BioSpace News Archive

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced regulatory updates for its approved products, VOQUEZNA™ TRIPLE PAK™ and VOQUEZNA DUAL PAK™, approved in the U.S. for the treatment of H. pylori infection, and its pending New Drug Application (NDA) for vonoprazan for the treatment of erosive esophagitis.

Sensus Healthcare, Inc. announces financial results for the three and 12 months ended December 31, 2022.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Thursday, February 16, at 2:20 p.m. ET.

Surgery Partners, Inc. announced the Company will release its fourth quarter 2022 results before the market opens on Wednesday, March 1, 2023, to be followed by a conference call at 8:30 a.m..

Hyperfine, Inc., the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable MRI system, announced the presentation of new data regarding the use of the Swoop® system in stroke patient follow-up at the 2023 International Stroke Conference in Dallas, Texas.

This week, Theradaptive, a leading biotechnology company specializing in therapeutic delivery platforms, presents a new abstract demonstrating the efficacy and safety of the company’s novel AMP2 protein technology in rabbit PLF and sheep interbody fusion models.

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023, after the U.S. financial markets close.

Syros Pharmaceuticals announced the grant of restricted stock unit awards for an aggregate of 12,400 shares of Syros common stock to two newly hired employees in connection with their commencement of employment with Syros.

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, announced consolidated financial results for the first quarter of fiscal 2023, ended December 31, 2022.

Axcella Therapeutics (Nasdaq: AXLA) today announced that CEO Bill Hinshaw will present a company update at SVB Securities’ 2023 Global Biopharma Conference, taking place virtually February 14-16, 2023.